WCLC25: Insights and Highlights from Dr. Stephen Liu

The 2025 IASLC World Conference on Lung Cancer (WCLC25) is being held from September 6–9, 2025, at the Fira de Barcelona Gran Via in Barcelona, Spain. This globally recognized conference brings together top clinicians, researchers, and industry experts to share and explore the latest developments in lung cancer research and treatment.

With a full agenda of presentations, expert panels, and in-depth discussions on the most current topics in thoracic oncology, WCLC25 serves as a premier forum for exchanging knowledge, identifying emerging trends, and fostering collaboration in the fight against lung cancer.

Throughout the conference, several key voices are offering compelling highlights and unique perspectives to enrich the experience. Among them is Dr. Stephen V. Liu—Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center—whose insights are helping to shape conversations and bring critical takeaways to a wider audience:

Dr. Paul Van Schil reflects on the advances and accomplishments, growth, collaboration, and progress:

“Dr. Paul Van Schil delivers his IASLC Presidential Address at WCLC25, reflecting on the advances and accomplishments, growth, collaboration, and progress. He now passes the IASLC Presidency to Professor Caicun Zhou as we move into the new year.”

Professor Caicun Zhou’s Vision for Lung Cancer Care at WCLC25:

“Professor Caicun Zhou delivers a stirring Presidential Address as he enters the IASLC presidency at WCLC25. Reminds us that lung cancer is a human experience – not just a disease – and we have to remember the patient behind the diagnosis. And that we cannot accept a world where some patients cannot get access to the best possible cancer care.”

Dr. John Varlotto presents EA5181:

“Dr. John Varlotto presents EA5181: phase II study of cuncurrent and consolidation durvalumab vs consolidation alone after CRT in unresectable stage III NSCLC at WCLC25. Superimposable curves: no improvement at all in OS (HR 1.03) or PFS (1.05) and similar toxicity.”

Dr. Nan Bi Presents Phase III LS-SCLC Radiation Study:

“Dr. Nan Bi at WCLC25 with a phase III study of hypofractionated (45Gy/15fx) or conventional fractionated radiation (60Gy/30fx) with concurrent chemotherapy for LS-SCLC. No OS difference but did not meet non-inferiority threshold. No PFS or LRFS differences seen.”

Dr. Corinne Faivre-Finn on Radiation Highlights from WCLC25 Plenary:

“Dr. Corinne Faivre-Finn discusses the radiation abstracts from the WCLC25 plenary session. Highlights the challenges of integrating radiation and immunotherapy – and caution with changing practice on phase II studies. For SCLC – hypofractionation is a good option but not yet SOC.”

Dr. Mariano Provencio Presents NADIM-ADJUVANT Trial at WCLC25:

“Dr. Mariano Provencio presents NADIM-ADJUVANT at WCLC25 – phase III study of adjuvant chemo vs chemo + immunotherapy in resected Ib-IIIA v8 NSCLC. Adding IO did not impact delivery. Trend to improvement in DFS (HR 0.65, p=0.085) though early crossing of curves. Cancer specific DFS looks very favorable, HR 0.54, 2y cancer specific DFS rate 83% vs 69%. No difference in OS but continues to mature.”

Dr. Tina Cascone’s Expert Discussion of NADIM-ADJUVANT at WCLC25:

“Dr. Tina Cascone with a masterful and balanced discussion of NADIM-ADJUVANT at WCLC25. Notes the control is no longer SOC and risks with the design. Imbalances including those with cardiac conditions which may have been relevant. Note EGFR/ALK/KEAP1 not known for many. While NADIM-ADJUVANT results encouraging, p did not cross early efficacy boundary and early crossing of curves leaves HR difficult to interpret. DFS from last dose allows comparison and suggests benefit from concurrent portion. Tremendous discussion from Dr. Tina Cascone.”

More from WCLC25 on OncoDaily.